JPRN-C000000097已完成2 期
A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancer - A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Prior radiotherapy to evaluable disease unless subsequent progression at that site 2. Prior brain metastases if not clinically stable after surgery and/or radiotherapy 3. Uncontrolled hypertension, unstable angina pectoris, myocardial infarction <6 months before enrollment or congestive heart failure 4. Active concomitant malignancy requiring treatment. 5. Uncontrolled serious active infection 6. Pre-existing grade 2 neuropathy 7. Pregnancy or lactation
研究者
相似试验
已完成
2 期
A clinical trial to study the effects of carboplatin / Paclitaxel and a new drug, CS- 7017, in patients with Non-Small Cell Lung CancerCTRI/2010/091/000491Daiichi Sankyo Pharma Development399 Thornall StreetEdison, NJUSA115
进行中（未招募）
不适用
Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer.endometrial cancerMedDRA version: 14.1Level: LLTClassification code 10014770Term: Endometrioid adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003301-16-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI108
未知
2 期
Phase II study in combination with Carboplatin and TS-1 for Cancer of unknown primaryCancer of unknown primaryJPRN-UMIN000001236ational Cancer Center Hospital, Tokyo35
进行中（未招募）
1 期
A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination .Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.MedDRA version: 20.0Level: LLTClassification code 10006888Term: Ca ovarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061269Term: Malignant peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002860-42-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE234
进行中（未招募）
2 期
A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine CarcinomasACTRN12616000958482Australasian Gastro-Intestinal Trials Group (AGITG)60